Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Genetic Determinants and Evolutionary History of Richter's Syndrome

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139456

Published: 2020

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136830

Published: 2020

Journal Articles

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Daniela Steinbrecher, PhD, Felix Seyfried, MD, Eugen Tausch, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Christof Schneider, MD

Blood (2019) 134 (Supplement_1): 1507.

https://doi.org/10.1182/blood-2019-127931

Published: 2019

Journal Articles

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, André Lechel, Sarah-Fee Katz, PhD, Eugen Tausch, Johannes Bloehdorn, MD, Daniela Steinbrecher, PhD, Vanni Torresi, Christof Schneider, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Lenhard Rudolph, Stephan Stilgenbauer

Blood (2019) 134 (Supplement_1): 1732.

https://doi.org/10.1182/blood-2019-126878

Published: 2019

Journal Articles

Ibrutinib Can Induce Complete Remissions and Sustained Responses in Refractory Cutaneous or Leg-Type Diffuse Large B-Cell Lymphoma

Johannes Bloehdorn, MD, Stephanie Ellen Weissinger, MD, Anca Sindrilaru, MD, Stefan Schoensteiner, MD, Thorsten Peters, MD, Peter Moeller, MD, Ralf Marienfeld, PhD, Andreas Viardot, MD

Blood (2018) 132 (Supplement 1): 4237.

https://doi.org/10.1182/blood-2018-99-117032

Published: 2018

Journal Articles

Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL

Laura Beckmann, MD, Valeska Berg, PhD, Clarissa Dickhut, Johannes Bloehdorn, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Malte Hülsemann, MD, Stefan Loroch, Olaf Merkel, Kirsten Fischer, MD, Clemens-Martin Wendtner, Stephan Stilgenbauer, Albert Sickmann, PhD, Michael Hallek, René Zahedi, PhD, Lukas P. Frenzel, MD

Blood (2018) 132 (Supplement 1): 583.

https://doi.org/10.1182/blood-2018-99-118235

Published: 2018

Journal Articles

NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23

Viola Close, MSc, William Close, MSc, Sabrina Julia Kugler, PhD, Michaela Reichenzeller, PhD, Deyan Yordanov Yosifov, PhD, Johannes Bloehdorn, MD, Leiling Pan, MSc, Eugen Tausch, MD, Mike-Andrew Westhoff, PhD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Franz Oswald, PhD, Daniel Mertens

Blood (2018) 132 (Supplement 1): 946.

https://doi.org/10.1182/blood-2018-99-114491

Published: 2018

Journal Articles

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Johannes Bloehdorn, MD, Julia Krzykalla, MSc, Billy Michael Chelliah Jebaraj, PhD, Karlheinz Holzmann, Dr. rer. nat., Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kathryn Humphrey, Michael Wenger, Eugen Tausch, MD, Christof Schneider, MD, Lars Bullinger, MD, Kirsten Fischer, MD, Michael Hallek, MD, Daniel Mertens, Axel Benner, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2018-99-116937

Published: 2018

Journal Articles

Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B.

Stephanie Ellen Weissinger, MD, Peter Moeller, MD, Ralf Marienfeld, PhD, Johannes Bloehdorn, MD, Andreas Viardot, MD

Blood (2018) 132 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2018-99-114551

Published: 2018

Journal Articles

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Daniela Steinbrecher, MSc, Felix Seyfried, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Christof Schneider, MD

Blood (2018) 132 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2018-99-115845

Published: 2018

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study

Blood (2014) 124 (21): 1991.

https://doi.org/10.1182/blood.V124.21.1991.1991

Published: 2014

Journal Articles

Genomic Mechanisms of 17p / TP53 Loss in Primary “ultra High-risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Veronica Teleanu, MD, Jennifer Edelmann, MD, Claudia Haferlach, MD, Stefan Ibach, Eugen Tausch, MD, Johannes Bloehdorn, MD, Veronique Leblond, MD PhD, Florence Cymbalista, MD, Alain Delmer, MD PhD, Michael Hallek, MD, Hartmut Doehner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 2184.

https://doi.org/10.1182/blood.V124.21.2184.2184

Published: 2014

Journal Articles

High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?

Jennifer Edelmann, MD, Eugen Tausch, MD, Johannes Bloehdorn, MD, Thorsten Zenz, MD, Kirsten Fischer, MD, Jasmin Bahlo, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1964.

https://doi.org/10.1182/blood.V124.21.1964.1964

Published: 2014

Journal Articles

High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Jennifer Edelmann, MD, Jenny Saub, Stefan Ibach, Karlheinz Holzmann, PhD, Eugen Tausch, MD, Johannes Bloehdorn, MD, Daniel Mertens, PhD, Thorsten Zenz, MD, Florence Cymbalista, MD, Veronique Leblond, MD PhD, Alain Delmer, MD PhD, John G. Gribben, MD DSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 3288.

https://doi.org/10.1182/blood.V124.21.3288.3288

Published: 2014

Journal Articles

High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial

Johannes Bloehdorn, MD, Martin Sill, PhD, Christian Langer, MD, Axel Benner, Dipl.Stat., Thorsten Zenz, MD, Andreas Bühler, MD, Raymonde Busch, PhD, Peter Dreger, MD, Ulrich Jäger, MD, Michael Hallek, M.D. Ph.D., Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1618.

https://doi.org/10.1182/blood.V122.21.1618.1618

Published: 2013

Journal Articles

Expression of Cereblon ( CRBN ) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma

Florian Kuchenbauer, MD, PhD, Johannes Bloehdorn, MD, Miriam Kull, MD, Peter Liebisch, MD, Veronica Teleanu, MD, Britta Kopp, Stefan Knop, Christian Straka, Hermann Einsele, Hartmut Döhner, MD, Christian Langer

Blood (2012) 120 (21): 1820.

https://doi.org/10.1182/blood.V120.21.1820.1820

Published: 2012

Journal Articles

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Johannes Bloehdorn, MD, Martin Sill, PhD, Andreas Bühler, MD, Silja Mack, MSc, Doris Winter, Lars Bullinger, MD, PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD, PhD, Daniel Mertens, PhD, Axel Benner, Dipl.Stat., Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 2874.

https://doi.org/10.1182/blood.V120.21.2874.2874

Published: 2012

NARROW

Genetic Determinants and Evolutionary History of Richter's Syndrome

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Ibrutinib Can Induce Complete Remissions and Sustained Responses in Refractory Cutaneous or Leg-Type Diffuse Large B-Cell Lymphoma

Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL

NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B.

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study

Genomic Mechanisms of 17p / TP53 Loss in Primary “ultra High-risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?

High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial

Expression of Cereblon ( CRBN ) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only